Skip to content

Free Flap Breast Reconstruction Using Virtual Surgical Planning and 3-D Modeling

Free Flap Breast Reconstruction Using Virtual Surgical Planning and 3-D Modeling

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03949491
Enrollment
38
Registered
2019-05-14
Start date
2020-12-01
Completion date
2022-08-01
Last updated
2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Reconstruction

Brief summary

The purpose of this study is to determine if 3D modeling and Virtual Planning Surgery can improve the clinical outcome with patient who have a mastectomy requiring breast reconstruction.

Detailed description

Primary objective: Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease dissection time and secondary perioperative complications including fat necrosis and donor site complications. Secondary objective: To propose incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes. This is a single-armed, prospective study to determine the feasibility of using 3-D virtual planning and medical modeling in breast cancer patients undergoing breast reconstruction

Interventions

PROCEDURE3D medical models

Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease both operative time and dissection time. This will also allow for the proposal of incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes, decrease donor site complications and improve patient satisfaction

Sponsors

Case Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects must have histologically or cytologically confirmed breast caner undergoing delayed or immediate breast reconstruction. * Performance statusECOG Performance status ≤ 2 * Subjects must have normal organ and marrow function as defined below: * Hemoglobin ≥ 10.0 g/dl * Leukocytes ≥ 3,000/mcL * Absolute neutrophil count ≥ 1,500/mcL * Platelet count ≥ 100,000/mcL * Total bilirubin within normal institutional limits * AST (SGOT) ≤ 2.5 X institutional upper limit of normal * ALT (SGPT) ≤ 2.5 X institutional upper limit of normal * Serum Creatinine within normal institutional limits * Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

* Subjects receiving any prior abdominoplasty or abdominal liposuction, or patient that plan on undergoing radiation therapy after reconstruction. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to IV contrast. * Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Pregnant or breastfeeding women are excluded from this study because IV contrast and CT scans have the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with breast cancer, breastfeeding should be discontinued. * Unsuitable donor site volume or vasculature based on pre-operative imaging or physical exam.

Design outcomes

Primary

MeasureTime frameDescription
Mean operative timeUp to 6 months after reconstructionMean operative time using 3D medical models of the abdomen to create a virtual plan to assist reconstruction.
Mean dissection timeUp to 6 months after reconstructionMean dissection time using 3D medical models of the abdomen to create a virtual plan to assist reconstruction.

Secondary

MeasureTime frameDescription
Aesthetic outcomes as measured by the Harris scaleUp to 1 year after reconstructionAesthetic outcomes as measured by the Harris scale, which ranges from 1-4, with higher scores indicating worse outcomes.
Donor site complicationsUp to 1 year after reconstructionNumber of donor site complications will be reported
Incidence of fat necrosis as measured by a grading system1 week, 2 weeks, 6 weeks, 3 months, and 6 months post reconstruction.Incidence of fat necrosis will be measured in the postoperative period using a classification system. Grade I necrosis will be defined as minimal requiring no surgical intervention; Grade II necrosis will be minor with some aesthetic defect requiring primary excision and closure; Grade III necrosis will be defined as requiring secondary procedures after excision to achieve satisfactory cosmesis; Grade IV necrosis will involve a necrosectomy requiring a either a completely new flap or at least a second flap to address such problems; Grade V necrosis will be defined as complete flap failure 5. Higher grade of fat necrosis is worse.
Patient satisfaction as measured by BREAST-Q scoresUp to 1 year after reconstructionPatient satisfaction as measured by BREAST-Q scores which ranges from 4-16, with higher scores indicating more satisfaction with breasts.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026